Effect of belimumab on patients with lupus nephritis and impaired kidney function: post hoc subgroup analysis of the phase III BLISS-LN trial.

Lupus Sci Med · 2026 · PMC13084980 · PMID 41986079

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although the belimumab group showed a trend towards earlier and more sustained response, differences were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.